Genocea Biosciences

100 Acorn Park Drive
Cambridge
Massachusetts
02140
United States

Tel: 617-876-8191
Fax: 617-876-8192

About Genocea Biosciences

Genocea aims to transform vaccine discovery and development to improve millions of lives. We use ATLAS™, our proprietary technology platform that rapidly identifies T cell antigens associated with protective immune responses in humans exposed to a pathogen. We have a pipeline of novel vaccine candidates that stimulate the T cell arm of the immune system, which is increasingly recognized as critical to generating protective immunity against a wide array of diseases.
Genocea’s pipeline includes programs addressing genital herpes, pneumococcus, chlamydia, malaria and cancer immunotherapy. We currently have two products in Phase 2 clinical development:
• GEN-003, an immunotherapy to treat patients with genital herpes. We reported positive top-line data from an ongoing Phase 2b dose optimization trial from the immediate post dosing 28-day observation period in May 2015. We identified an improved dose of 60µg per protein/75µg of adjuvant, which demonstrated a highly statistically significant reduction (p>0.0001) from baseline in the viral shedding rate (55%) and genital lesion rate (60%). Data from the six-month and 12-month observation periods in this trial is expected in the fourth quarter of 2015 and the first quarter of 2016, respectively.
Data from the prior Phase 1/2a trial was the first time a therapeutic vaccine candidate has demonstrated significant reductions in the rates of viral shedding and genital lesions in genital herpes patients.

• GEN-004, a universal vaccine which is in Phase 2 development to prevent infections caused by all serotypes of pneumococcus. We have completed enrollment in a Phase 2 human challenge clinical trial and expect to report top-line data in the fourth quarter of 2015.
In a prior Phase 1 study, GEN-004 met its safety, tolerability and immunogenicity goals, including measurable increases in the blood of T helper 17 (TH17) cells, a rare cell type that provides immunity at epithelial and mucosal surfaces.

193 articles with Genocea Biosciences

Genocea Announces FDA Acceptance of GEN-011 IND ApplicationNovel adoptive T cell therapy targets checkpoint-refractory solid tumors with neoantigen-specific T cells from peripheral blood

9/22/2020

Genocea Biosciences, Inc . (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Investigational New Drug (IND) Application for GEN-011, an adoptive T cell therapy targeting neoantigens and designed to improve upon the limitations of TIL and TCR therapies. The IND allows Genocea to initiate a Phase 1/2a cl
Genocea Presents Follow-up Data from GEN-009 Neoantigen Vaccine Phase 1/2a Trial at ESMO Virtual Congress 2020

9/17/2020

Step-down responses to GEN-009, with 3 objective responses (2 PR, 1 CR) in the first 5 patients, suggests added benefit to PD-1 inhibitor therapy
Genocea to Present at the ESMO Virtual Congress and Two Investor Conferences in September 2020

9/3/2020

Genocea Biosciences, Inc. announced that the company will present incremental follow-up data, including additional tumor scan results and detailed immunogenicity data on the first five patients from Part B of the ongoing GEN-009 Phase 1/2 a trial at the European Society for Medical Oncology Virtual Congress 2020 from September 19-21.
Genocea to Present Positive Preliminary Clinical Data Evaluating Neoantigen Vaccine GEN-009 in Combination with Checkpoint Inhibitors

7/30/2020

Genocea Biosciences, Inc., a biopharmaceutical company developing next-generation neoantigen immunotherapies, will present initial clinical data on the first five patients from Part B of the ongoing Phase 1/2a study, which explores the combination of Genocea’s neoantigen vaccine, GEN-009 and checkpoint inhibitor-based regimens in advanced solid tumors.
Genocea Provides Second Quarter 2020 Corporate Update

7/23/2020

Upcoming GEN-009 data update planned for July 30th at 8 a.m. EDT Filed IND application for GEN-011 and is working with the FDA to provide additional information Private Placement with Leading Life Science Investment Funds.
Genocea Announces Private Placement Financing of Up to $80 Million

7/22/2020

Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, today announced that it has entered into a private placement led by an undisclosed leading U.S. public investment fund specializing in life sciences as well as certain existing and new investors providing for the purchase of up to approximately $80 million of its common stock and warrants to purchase shares of Genocea commo
Genocea Biosciences Provides Clinical Update

7/20/2020

Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced updates to its clinical programs, the neoantigen vaccine GEN-009 and the neoantigen cell therapy, GEN-011. GEN-009 On July 30, 2020, the Company will share initial clinical data on the first 5 patients from Part B of the ongoing Phase 1/2a clinical trial exploring the combination of GEN-009 and imm
Genocea to Host Second Quarter 2020 Corporate Update Conference Call & Webcast

7/16/2020

Genocea Biosciences, Inc . (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, will host its second quarter 2020 financial results and corporate update conference call and live audio webcast on Thursday, July 23rd at 8:30 a.m. EDT. Interested participants may access the conference call by dialing (844) 826-0619 (domestic) or (315) 625-6883 (international) and referring to conference ID numbe
Genocea to Present Data that Reveal New Understanding of ATLASTM-Identified InhibigenTM Biology at AACR Virtual Annual Meeting II

6/22/2020

Inhibigens (inhibitory antigens) are detrimental an otherwise protective immunotherapy Inhibigens alter the tumor microenvironment and drive tumor hyperprogression Inhibigens abolish both global and tumor antigen-specific T cell activity CAMBRIDGE, Mass., June 22, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc . (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today presented preclinical data that offers new and important insi
Genocea Files IND Application for GEN-011, a T cell Therapy Designed to Improve on Current Limitations of TIL TherapyPreliminary clinical data expected mid-2021

6/15/2020

Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced the filing of an Investigational New Drug (IND) Application with the U.S. Food and Drug Administration (FDA) to begin a Phase 1/2a clinical study of GEN-011 in a range of tumor types, with a focus on patients who have failed standard-of-care checkpoint inhibitor therapy.
Genocea Presents Updated Long-term Safety, Immunogenicity and Durability Data from GEN-009 Neoantigen Vaccine Phase 1/2a Trial Part A at Virtual ASCO 2020

5/29/2020

Data show immune responses occur rapidly after only two vaccinations and can be sustained for more than one year
Genocea Announces Material Transfer and License Option Agreement with Shionogi for Proprietary GEN-003 HSV-2 Antigens

5/19/2020

Genocea Biosciences, Inc . (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced it has entered into a material transfer agreement (MTA) and exclusive license option with Shionogi & Co., Ltd. to develop a novel HSV-2 vaccine using Genocea’s proprietary HSV-2 antigens from the GEN-003 program, which the company discontinued in 2017. Under the terms of the agreement, Shionogi
Genocea to Present Long-term Follow-up Data from GEN-009 Neoantigen Vaccine at Virtual ASCO 2020

5/13/2020

Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, will present updated durability, safety and immunogenicity clinical data from Part A of its ongoing Phase 1/2a trial for GEN-009, the company’s lead neoantigen vaccine candidate at the virtual 2020 American Society for Clinical Oncology (ASCO) Annual Meeting from May 29-31.
Genocea Introduces GEN-011, a Transformational T cell Therapy Designed to Improve on Current Limitations of TIL TherapyGEN-011 IND filing by end of Q2 with preliminary clinical data expected in 1H 2021

5/12/2020

Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, hosted a KOL symposium today with Dr. Eric Tran, Assistant Member at the Earle A. Chiles Research Institute in the Providence Cancer Institute reflecting on the T cell therapy landscape, while Genocea provided an in-depth profile of GEN-011 – Genocea’s neoantigen cell therapy.
REMINDER: Genocea to Host KOL Symposium Highlighting GEN-011’s Potential to Transform T cell Therapy for Solid TumorsCall scheduled for May 12th from 12:00 – 1:30 p.m. EDT

5/11/2020

Genocea Biosciences, Inc., a biopharmaceutical company developing next-generation neoantigen immunotherapies, will host a KOL symposium with a live Q&A for analysts and investors to reflect on the progress of the T cell therapy landscape and provide an in-depth profile of GEN-011 – Genocea’s neoantigen cell therapy – on Tuesday, May 12th at 12:00 p.m. EDT.
Genocea to Host KOL Symposium Highlighting GEN-011’s Potential to Transform T cell Therapy for Solid TumorsCall scheduled for May 12th from 12:00 – 1:30 p.m. EDT

5/5/2020

Genocea Biosciences, Inc. will host a KOL symposium with a live Q&A for analysts and investors to reflect on the progress of the T cell therapy landscape and provide an in-depth profile of GEN-011 – Genocea’s neoantigen cell therapy – on Tuesday, May 12th at 12:00 p.m. EDT.
Genocea Provides First Quarter 2020 Corporate Update

4/30/2020

Genocea Biosciences, Inc., a biopharmaceutical company developing next-generation neoantigen immunotherapies, reported its operating and financial results for the first quarter ended March 31, 2020.
Genocea to Present Virtually at the 19th Annual Needham Healthcare Conference

4/8/2020

Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that Chip Clark, president and chief executive officer, will present a corporate overview at the 19th Annual Needham Virtual Healthcare Conference on Wednesday, April 15th at 9:20 a.m. EDT.
Genocea to Present at the Cowen & Company 40th Annual Health Care Conference

2/26/2020

Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that Chip Clark, president and chief executive officer, will present a corporate overview at the Cowen & Company 40th Annual Health Care Conference on Monday, March 2nd at 2:50pm ET in New York, NY.
Genocea to Present at the SVB Leerink 9th Annual Global Healthcare Conference

2/20/2020

Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that Chip Clark, president and chief executive officer, will present a corporate overview at the SVB Leerink 9th Annual Global Healthcare Conference on Thursday, February 27th at 9:00 a.m. EST in New York, NY.